Nerandomilast for Myositis

(VERANDA™-IIM Trial)

This trial tests a new medicine called nerandomilast to determine its effectiveness for people with active idiopathic inflammatory myopathy (IIM), a condition that causes muscle inflammation and weakness. Participants will take either nerandomilast or a placebo, which looks the same but contains no active ingredient, for one year. The trial aims to assess whether nerandomilast can improve symptoms such as muscle pain and weakness. Individuals diagnosed with IIM, experiencing moderate to severe muscle problems, and already undergoing treatment might be suitable candidates for this study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to a potentially groundbreaking treatment.

Research has shown that nerandomilast has been tested for safety in various conditions, such as lung disease. Studies indicate it is generally safe and well-tolerated. Diarrhea is the most common side effect and can be managed. In some studies, participants taking nerandomilast discontinued treatment at a rate similar to those on a placebo, suggesting it doesn't cause many serious side effects. However, more information is needed about its long-term safety in myositis. So far, evidence suggests it could be a safe option.¹²³⁴⁵

Nerandomilast is unique because it offers a new approach to treating myositis, a condition typically managed with corticosteroids and immunosuppressants. Unlike these standard treatments, which broadly suppress the immune system and can have significant side effects, nerandomilast targets specific pathways involved in the inflammation process. Researchers are excited about its potential to reduce inflammation more precisely and with fewer side effects, potentially improving patients' quality of life.

Research has shown that nerandomilast may help treat idiopathic inflammatory myopathy (IIM), a condition that causes muscle inflammation. In some studies, patients taking nerandomilast experienced less muscle inflammation and showed improvements in their condition. The treatment also slowed the decline in lung function, as measured by forced vital capacity (FVC). However, improvements in lung symptoms were not always strong enough to rule out chance. Overall, various studies have found nerandomilast to be safe and well-tolerated by patients. Participants in this trial will receive either nerandomilast or a placebo to further evaluate its effectiveness and safety.¹²³⁵⁶